Collaborations

 

Pharma Holdings is a privately-owned pharmaceutical company focused on anti-microbials. Our mission is to improve human health. The Company develops novel drugs for the treatment of resistant bacterial and fungal infections. This has resulted in an exciting pipeline – comprising ultrabroad-spectrum antimicrobials with a mechanism of action which reduces the probability of resistance development. For potential partners, we offer attractive co-development and licensing opportunities.

LTX-109 product highlights:

  • Novel mechanism of action
  • Ultra-rapid, bactericidal
  • Broad spectrum of activity (gram+ bacteria, gram – bacteria, yeasts and fungi)
  • Low propensity for resistance development
  • Active against drug-resistant strains
  • Effective against fungal and bacterial biofilms
  • Superior efficacy compared to market leaders
Close Menu